Objectives: To determine if fetal echo measurements of the size and shape of the 4 chamber heart (4CV), or the size, shape and function of the right and left ventricles (RV, LV) can successfully discriminate fetuses with true coarctation of the aorta (CoA) from fetuses with suspected CoA). Methods: Eighty-eight fetuses with the presumptive prenatal suspicion of CoA were identified from a cardiology database. The size and shape of the 4CV were measured (area, circumference, and sphericity index). Using speckle-tracking software the RV and LV size and shape (area, length, 24-segment transverse diameter, and 24-segment sphericity index (SI)) were measured as well as the ventricular global, longitudinal, and circumferential function. Using the mean and standard deviation from 200 control fetuses, the z-score for each of the above measurements was computed and used for logistic regression analysis. Measurements of the aortic valve and transverse aortic arch were not considered in the analysis or prenatal classification of fetuses in this study. The examiner who performed the above measurements was blinded to the postnatal diagnosis. Objectives: In fetuses diagnosed with an aberrant right subclavian artery (ARSA) and no extra-cardiac anomalies, we aimed to establish the frequency of chromosomal anomaly diagnosed with single nucleotide polymorphism microarray analysis, particularly focusing on microduplications or microdeletions which would have gone undetected by conventional karyotyping or cfDNA screening. Methods: Retrospective study of fetal ultrasounds between 2012 and 2017 in an Australian tertiary referral centre. All patients had detailed tertiary level morphology scan and echocardiography with a fetal cardiologist to assess the presence of fetal abnormalities. Outcomes of interest were survival and frequency of chromosomal anomalies. Results: A total of 63 patients were identified with ARSA, of which 45 (71%) were apparently isolated. Five of these patients had previously declined screening for chromosomal anomalies; 36/45 had a documented screening test (30 cfDNA, 6 first trimester screening with combined ultrasound and biochemistry) and 1 had an amniocentesis prior to the morphology scan for paternal translocation. One of the patients tested by cfDNA had a high-risk result for Trisomy 21 (T21); the remainder had low-risk results. A total of 14 amniocenteses were performed: 12 had normal microarray analysis, 1 confirmed T21 and one had a copy number variant of unknown clinical significance. Conclusions: The frequency of clinically significant chromosomal anomalies in fetuses with isolated ARSA following a low risk screening test result is low. Out of the 35 patients with low-risk screening tests none had T21. The confirmed chromosomal anomaly in presumably isolated ARSA was already suspected on cfDNA and had an increased nuchal translucency thickness.
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In the presence of an ARSA and a background of low-risk screening, parents can be reassured that the risk of a chromosomal abnormality is low and the finding is probably a normal variant.
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The ventricular function assessment in fetus with tricuspid regurgitation by VVI
